Radiomics and theranostics with molecular and metabolic probes in prostate cancer: toward a personalized approach
Sign Up to like & getrecommendations! Published in 2023 at "Expert Review of Molecular Diagnostics"
DOI: 10.1080/14737159.2023.2192351
Abstract: ABSTRACT Introduction In the last decade, two new radionuclide-based therapies, 223Radichloride and radioligand therapy (RLT) targeting prostate-specific membrane antigen (PSMA), have been approved by the regulatory authorities for the management of castrate-resistant prostate cancer (PCa).… read more here.
Keywords: prostate cancer; molecular metabolic; theranostics molecular; radiomics theranostics ... See more keywords